UroGen Pharma Ltd. (NASDAQ:URGN) was the target of some unusual options trading on Thursday. Stock traders purchased 2,353 call options on the stock. This is an increase of 2,099% compared to the average volume of 107 call options.
In other UroGen Pharma news, CFO Peter P. Pfreundschuh sold 2,400 shares of UroGen Pharma stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $21.77, for a total value of $52,248.00. Following the completion of the sale, the chief financial officer now owns 12,805 shares of the company's stock, valued at approximately $278,764.85. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 2,849 shares of company stock worth $61,394 over the last ninety days. 12.00% of the stock is currently owned by insiders.
A number of large investors have recently added to or reduced their stakes in URGN. BlackRock Inc. boosted its holdings in shares of UroGen Pharma by 1.4% in the 3rd quarter. BlackRock Inc. now owns 1,485,601 shares of the company's stock valued at $28,657,000 after acquiring an additional 19,796 shares during the last quarter. Phoenix Holdings Ltd. raised its stake in shares of UroGen Pharma by 0.5% during the 3rd quarter. Phoenix Holdings Ltd. now owns 901,979 shares of the company's stock valued at $16,405,000 after buying an additional 4,515 shares during the last quarter. FMR LLC raised its stake in shares of UroGen Pharma by 5.8% during the 1st quarter. FMR LLC now owns 588,203 shares of the company's stock valued at $21,728,000 after buying an additional 32,200 shares during the last quarter. Horton Capital Management LLC lifted its holdings in shares of UroGen Pharma by 52.4% in the 2nd quarter. Horton Capital Management LLC now owns 383,428 shares of the company's stock valued at $10,015,000 after buying an additional 131,809 shares during the period. Finally, Nuveen Asset Management LLC boosted its stake in shares of UroGen Pharma by 24.5% in the second quarter. Nuveen Asset Management LLC now owns 337,149 shares of the company's stock worth $8,807,000 after buying an additional 66,316 shares during the last quarter. 69.95% of the stock is owned by institutional investors and hedge funds.
Several research firms have issued reports on URGN. ValuEngine cut shares of UroGen Pharma from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 26th. HC Wainwright restated a "buy" rating on shares of UroGen Pharma in a research report on Tuesday, September 8th. Oppenheimer cut their target price on shares of UroGen Pharma from $48.00 to $40.00 in a research report on Tuesday, November 10th. Stifel Nicolaus reiterated a "buy" rating and set a $46.00 target price on shares of UroGen Pharma in a research note on Monday, August 10th. Finally, JPMorgan Chase & Co. dropped their price target on UroGen Pharma from $31.00 to $26.00 in a research note on Monday, September 21st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company's stock. The company presently has an average rating of "Buy" and an average price target of $39.00.
Shares of URGN stock opened at $20.58 on Friday. UroGen Pharma has a 12 month low of $13.12 and a 12 month high of $35.21. The stock has a market cap of $430.06 million, a P/E ratio of -3.35 and a beta of 1.69. The company has a 50 day simple moving average of $22.28 and a two-hundred day simple moving average of $23.45.
UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Monday, November 9th. The company reported ($1.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.47) by $0.16. The business had revenue of $3.46 million for the quarter, compared to the consensus estimate of $3.21 million. On average, sell-side analysts predict that UroGen Pharma will post -6.14 earnings per share for the current year.
UroGen Pharma Company Profile
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company's lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer.
Recommended Story: Growth and Income Funds
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
20 Stocks Wall Street Analysts Love the Most
Every trading day, between 500 and 800 new recommendations and research reports are issued by sell-side equities research analysts. There are between 300 and 500 brokerages and research houses that issue ratings, price targets and recommendations and more than 5,000 securities around the world that regularly receive coverage from research analysts.
MarketBeat has tracked more than 170,000 distinct analyst recommendations in the last 12 months alone. Given the volume of ratings changes that occur each day, it can be difficult to sift through the noise.
Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when more than a dozen different analysts from different brokerages and research firm are giving "strong buy" and "buy" ratings to the same stock.
This slide show lists the 20 companies that have the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.
View the "20 Stocks Wall Street Analysts Love the Most".